: Labcorp to spin off its clinical research organization under the name Fortrea


CORRECTION: An earlier version of this report incorrectly stated that Labcorp is spinning off a second business. It is not. The company only plans to spin off its clinical research organization. The report has been corrected.

Labcorp LH, -0.53% said Thursday that it plans to spin off its clinical development business into a publicly traded clinical research organization, or CRO, in mid-2023. The name of the planned spin-off is Fortrea, and it will employ about 19,000 people under CEO Tom Pike. Labcorp will retain its diagnostics, central labs, and early development research labs business. Labcorp’s stock is down 12.6% over the past year, while the broader S&P 500 SPX, +0.30% has declined 8.9%.

This article was originally published by Marketwatch.com. Read the original article here.

Previous articleEconomic Report: Jobless claims climb 13,000 to 196,000 — but are still near pandemic-era lows
Next articleMetals Stocks: Gold prices turn lower as investors await U.S. January inflation report


Please enter your comment!
Please enter your name here